Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.7K
Second Order systems II01:18

Second Order systems II

412
In an underdamped second-order system, where the damping ratio ζ is between 0 and 1, a unit-step input results in a transfer function that, when transformed using the inverse Laplace method, reveals the output response. The output exhibits a damped sinusoidal oscillation, and the difference between the input and output is termed the error signal. This error signal also demonstrates damped oscillatory behavior. Eventually, as the system reaches a steady state, the error diminishes to zero.
412
First Order Systems01:21

First Order Systems

433
First-order systems, such as RC circuits, are foundational in understanding dynamic systems due to their straightforward input-output relationship. Analyzing their responses to different input functions under zero initial conditions reveals significant insights into system behavior.
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
433
Second Order systems I01:20

Second Order systems I

603
A servo system exemplifies a second-order system, featuring a proportional controller and load elements that ensure the output position aligns with the input position. The relationship between these components is described by a second-order differential equation. Applying the Laplace transform under zero initial conditions yields the transfer function, showing how inputs are converted to outputs in the system.
By reinterpreting the system, one can derive the closed-loop transfer function, which...
603
Health Information Technology and Healthcare Information System01:30

Health Information Technology and Healthcare Information System

3.4K
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
3.4K
Thermodynamic Systems01:06

Thermodynamic Systems

8.2K
A thermodynamic system is a set of objects whose thermodynamic properties are of interest. The system is considered to be embedded in its surroundings or the environment. The system and its environment can exchange heat and do work on each other through a boundary that separates them. However, the immediate surroundings of the system interact with it directly and therefore have a much stronger influence on its behavior and properties.
Consider an example of  tea boiling in a kettle. The...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex opioid driven modulation of glutamatergic and cholinergic neurotransmission in a GABAergic brain nucleus associated with emotion, reward and addiction.

bioRxiv : the preprint server for biology·2025
Same author

Evolution of cortical neurons supporting human cognition.

Trends in cognitive sciences·2022
Same author

Verbal and General IQ Associate with Supragranular Layer Thickness and Cell Properties of the Left Temporal Cortex.

Cerebral cortex (New York, N.Y. : 1991)·2021
Same author

Fertility preservation in women with cancer and afterward.

Climacteric : the journal of the International Menopause Society·2019
Same author

Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis.

Oncogene·2018
Same author

Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.

Journal of viral hepatitis·2017
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

Usability Evaluation of Augmented Reality: A Neuro-Information-Systems Study
05:43

Usability Evaluation of Augmented Reality: A Neuro-Information-Systems Study

Published on: November 30, 2022

3.0K

Technology evaluation: IMC-1C11, ImClone Systems.

S Hunt1

  • 1dshunt@easynet.co.uk

Current Opinion in Molecular Therapeutics
|August 30, 2001
PubMed
Summary
This summary is machine-generated.

ImClone is developing IMC-IC11, a novel antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2), for cancer treatment. This therapy aims to inhibit tumor growth and potentially induce regression, showing promise in early trials.

More Related Videos

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing
09:06

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing

Published on: July 3, 2020

7.8K
Site-specific Bacterial Chromosome Engineering: ΦC31 Integrase Mediated Cassette Exchange (IMCE)
08:21

Site-specific Bacterial Chromosome Engineering: ΦC31 Integrase Mediated Cassette Exchange (IMCE)

Published on: March 16, 2012

16.1K

Related Experiment Videos

Last Updated: Feb 9, 2026

Usability Evaluation of Augmented Reality: A Neuro-Information-Systems Study
05:43

Usability Evaluation of Augmented Reality: A Neuro-Information-Systems Study

Published on: November 30, 2022

3.0K
Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing
09:06

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing

Published on: July 3, 2020

7.8K
Site-specific Bacterial Chromosome Engineering: ΦC31 Integrase Mediated Cassette Exchange (IMCE)
08:21

Site-specific Bacterial Chromosome Engineering: ΦC31 Integrase Mediated Cassette Exchange (IMCE)

Published on: March 16, 2012

16.1K

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Angiogenesis is crucial for tumor growth and metastasis.
  • Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a key mediator of angiogenesis.
  • Targeting VEGFR-2 offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To develop and evaluate IMC-IC11, a chimeric monoclonal antibody targeting VEGFR-2.
  • To assess the anti-angiogenic and anti-tumor efficacy of IMC-IC11.
  • To explore the potential of anti-VEGFR-2 antibodies in cancer therapy.

Main Methods:

  • Development of IMC-IC11, a monoclonal antibody specific to VEGFR-2.
  • Preclinical studies with related antibody DC-101 demonstrating tumor growth inhibition and regression.
  • Phase I clinical trials for colorectal carcinoma treatment.

Main Results:

  • The antibody DC-101 showed significant inhibition of glioblastoma tumor growth and regression.
  • IMC-IC11 is undergoing Phase I trials for colorectal carcinoma.
  • Patents have been granted for antibodies targeting the extracellular portion of the FLK-1/KDR receptor.

Conclusions:

  • Anti-VEGFR-2 antibodies, such as IMC-IC11, hold significant therapeutic potential in oncology.
  • Targeting angiogenesis via VEGFR-2 inhibition is a validated strategy for cancer treatment.
  • Further clinical evaluation of IMC-IC11 is warranted.